Covered recipient · General Payments record
JOEL R SAPER
Allopathic & Osteopathic Physicians Psychiatry & Neurology Pain Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$867.79
4 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $742.80 | 3 |
| Food and Beverage | $124.99 | 1 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Promius Pharma LLC | $720.40 | 2 |
| Lundbeck LLC | $147.39 | 2 |
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOEL R SAPER
NPI 1891888095 · CMS profile ID 358295
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Pain Medicine
ANN ARBOR, MI
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). JOEL R SAPER, NPI 1891888095, CMS profile ID 358295. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- JOEL R SAPER, NPI 1891888095, CMS profile ID 358295, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1891888095?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
4 matching records · $867.79 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–4 of 4.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lundbeck LLC | $22.40 | 11/21/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684345371 | CMS |
| Lundbeck LLC | $124.99 | 11/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684345377 | CMS |
| Promius Pharma LLC | $574.40 | 02/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701097285 | CMS |
| Promius Pharma LLC | $146.00 | 01/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701097283 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2024
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $741,643.58 | 208 |
| PY2024 | Principal investigator | $778,871.45 | 258 |
| PY2023 | Recipient | $188,670.14 | 42 |
| PY2023 | Principal investigator | $817,852.03 | 284 |
| PY2022 | Recipient | $694.00 | 1 |
| PY2022 | Principal investigator | $856,999.67 | 290 |
| PY2021 | Principal investigator | $1,105,932.40 | 208 |
| PY2020 | Principal investigator | $729,753.82 | 96 |
| PY2019 | Recipient | $20,043.40 | 4 |
| PY2019 | Principal investigator | $688,115.98 | 92 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
326 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $942.50 | 12/31/2023 | Non-covered Recipient Entity MI HEADACHE & NEUROLOGICAL INSTITUTE | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 998413225 |
| Principal investigator 1 | ABBVIE INC. | $927.00 | 12/31/2023 | Non-covered Recipient Entity MI HEADACHE & NEUROLOGICAL INSTITUTE | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 998413227 |
| Recipient | PFIZER INC. | $1,268.15 | 12/27/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045897043 |
| Recipient | PFIZER INC. | $15,163.90 | 12/27/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1045958913 |
| Recipient | PFIZER INC. | $812.00 | 12/27/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046136617 |
| Recipient | PFIZER INC. | $1,692.05 | 12/27/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046271361 |
| Recipient | PFIZER INC. | $5,167.05 | 12/22/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1045955801 |
| Recipient | PFIZER INC. | $2,498.31 | 12/21/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046270707 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,455.40 | 12/19/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811233 |
| Recipient | PFIZER INC. | $5,551.93 | 12/14/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046028777 |
| Principal investigator 1 | ABBVIE INC. | $3,720.00 | 12/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 998411531 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 12/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 998411533 |
| Principal investigator 1 | H. Lundbeck A S | $1,000.00 | 12/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059240031 |
| Principal investigator 1 | ABBVIE INC. | $372.60 | 12/12/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 998411453 |
| Principal investigator 1 | ABBVIE INC. | $22.50 | 12/12/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998411497 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,776.50 | 12/12/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811195 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,910.80 | 12/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811183 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $81.00 | 12/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811281 |
| Recipient | PFIZER INC. | $750.00 | 12/07/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046059329 |
| Recipient | PFIZER INC. | $40.50 | 12/07/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046273471 |
| Principal investigator 1 | ABBVIE INC. | $9,406.00 | 12/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 998409373 |
| Principal investigator 1 | ABBVIE INC. | $5,891.15 | 12/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 998409375 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,205.00 | 11/30/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811095 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,154.25 | 11/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811269 |
| Principal investigator 1 | PFIZER INC. | $16,784.60 | 11/24/2023 | Non-covered Recipient Entity 1 | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046177767 |
| Principal investigator 1 | PFIZER INC. | $609.00 | 11/24/2023 | Non-covered Recipient Entity 1 | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046186141 |
| Principal investigator 1 | PFIZER INC. | $1,310.72 | 11/22/2023 | Non-covered Recipient Entity 1 | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046212651 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,461.80 | 11/21/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811243 |
| Principal investigator 1 | H. Lundbeck A S | $1,618.52 | 11/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059239515 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,873.15 | 11/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811207 |
| Principal investigator 1 | H. Lundbeck A S | $6,500.00 | 11/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | EPTINEZUMAB IN PARTICIPANTS WITH EPISODIC CLUSTER HEADACHE (ALLEVIATE) | No dispute reported | 06/30/2026 | 1059239417 |
| Principal investigator 1 | PFIZER INC. | $3,456.34 | 11/16/2023 | Non-covered Recipient Entity 1 | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045970875 |
| Principal investigator 1 | PFIZER INC. | $2,892.03 | 11/16/2023 | Non-covered Recipient Entity 1 | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046011391 |
| Principal investigator 1 | PFIZER INC. | $4,506.08 | 11/16/2023 | Non-covered Recipient Entity 1 | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046034163 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 11/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 998408079 |
| Principal investigator 1 | ABBVIE INC. | $808.65 | 11/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 998408081 |
| Principal investigator 1 | PFIZER INC. | $658.80 | 11/09/2023 | Non-covered Recipient Entity 1 | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046109871 |
| Principal investigator 1 | ABBVIE INC. | $75.00 | 11/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 998407077 |
| Principal investigator 1 | ABBVIE INC. | $2,910.00 | 11/07/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998407009 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,873.15 | 11/07/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811169 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,546.00 | 11/02/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811131 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $639.90 | 11/02/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811147 |
| Principal investigator 1 | H. Lundbeck A S | $33.75 | 10/27/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059239163 |
| Principal investigator 1 | H. Lundbeck A S | $6,100.00 | 10/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A STUDY IN CHILDREN AND YOUNG PEOPLE WITH MIGRAINE TO LEARN WHAT THE BODY DOES TO EPTINEZUMAB | No dispute reported | 06/30/2026 | 1059239125 |
| Principal investigator 1 | H. Lundbeck A S | $3,332.96 | 10/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A STUDY IN CHILDREN AND YOUNG PEOPLE WITH MIGRAINE TO LEARN WHAT THE BODY DOES TO EPTINEZUMAB | No dispute reported | 06/30/2026 | 1059239130 |
| Principal investigator 1 | H. Lundbeck A S | $3,332.96 | 10/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A STUDY IN CHILDREN AND YOUNG PEOPLE WITH MIGRAINE TO LEARN WHAT THE BODY DOES TO EPTINEZUMAB | No dispute reported | 06/30/2026 | 1059239135 |
| Principal investigator 1 | H. Lundbeck A S | $6,100.00 | 10/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A STUDY IN CHILDREN AND YOUNG PEOPLE WITH MIGRAINE TO LEARN WHAT THE BODY DOES TO EPTINEZUMAB | No dispute reported | 06/30/2026 | 1059239141 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,711.90 | 10/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811071 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,583.65 | 10/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811257 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 10/20/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035812681 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 10/20/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035813107 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 10/20/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035813119 |
| Recipient | PFIZER INC. | $1,250.00 | 10/19/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045895719 |
| Recipient | PFIZER INC. | $1,000.00 | 10/19/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046102597 |
| Recipient | PFIZER INC. | $4,970.34 | 10/19/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046102785 |
| Recipient | PFIZER INC. | $2,186.03 | 10/19/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046121149 |
| Recipient | PFIZER INC. | $25,693.70 | 10/19/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046131145 |
| Recipient | PFIZER INC. | $837.50 | 10/19/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046141603 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 10/18/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998404423 |
| Principal investigator 1 | ABBVIE INC. | $630.00 | 10/18/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998404425 |
| Principal investigator 1 | ABBVIE INC. | $40.50 | 10/18/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 998404427 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,240.30 | 10/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811219 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $40.50 | 10/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811293 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 10/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035812669 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 10/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035813083 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 10/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035813095 |
| Principal investigator 1 | H. Lundbeck A S | $10,000.00 | 10/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) | No dispute reported | 06/30/2026 | 1059238981 |
| Principal investigator 1 | H. Lundbeck A S | $3,000.00 | 10/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY OF EPTINEZUMAB IN PEDIATRIC PARTICIPANTS WITH EPISODIC MIGRAINE (PROSPECT-1) | No dispute reported | 06/30/2026 | 1059238987 |
| Recipient | PFIZER INC. | $7,031.94 | 10/12/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1045922723 |
| Recipient | PFIZER INC. | $202.50 | 10/12/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046212635 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $743.00 | 10/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811059 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $11,025.00 | 10/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811083 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,486.00 | 10/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811109 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,410.00 | 10/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811121 |
| Principal investigator 1 | ABBVIE INC. | $8,852.25 | 10/05/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998402501 |
| Recipient | PFIZER INC. | $958.03 | 10/05/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046024777 |
| Recipient | PFIZER INC. | $5,381.39 | 10/05/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046302625 |
| Principal investigator 1 | ABBVIE INC. | $2,025.00 | 10/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 998401843 |
| Principal investigator 1 | ABBVIE INC. | $3,028.32 | 10/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 998401907 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,487.70 | 10/03/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811045 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,295.55 | 10/03/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811157 |
| Principal investigator 1 | H. Lundbeck A S | $122.20 | 09/27/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) | No dispute reported | 06/30/2026 | 1059238387 |
| Recipient | PFIZER INC. | $500.00 | 09/26/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046014497 |
| Recipient | PFIZER INC. | $2,961.29 | 09/26/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046034149 |
| Recipient | PFIZER INC. | $337.50 | 09/26/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046074505 |
| Principal investigator 1 | H. Lundbeck A S | $1,000.00 | 09/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) | No dispute reported | 06/30/2026 | 1059238333 |
| Recipient | PFIZER INC. | $3,417.86 | 09/21/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045956789 |
| Recipient | PFIZER INC. | $11,478.37 | 09/21/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046177707 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,784.30 | 09/21/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810971 |
| Principal investigator 1 | ABBVIE INC. | $1,984.50 | 09/20/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998400175 |
| Principal investigator 1 | H. Lundbeck A S | $1,067.04 | 09/20/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) | No dispute reported | 06/30/2026 | 1059238201 |
| Principal investigator 1 | H. Lundbeck A S | $893.44 | 09/18/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) | No dispute reported | 06/30/2026 | 1059238195 |
| Principal investigator 1 | H. Lundbeck A S | $1,002.92 | 09/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059238189 |
| Recipient | PFIZER INC. | $202.50 | 09/14/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1045999707 |
| Recipient | PFIZER INC. | $6,923.30 | 09/14/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046032001 |
| Principal investigator 1 | ABBVIE INC. | $521.44 | 09/06/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998398437 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $10,009.20 | 09/06/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810911 |
| Principal investigator 1 | ABBVIE INC. | $1,514.16 | 09/05/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 998398183 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,391.50 | 09/01/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810777 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $40.50 | 09/01/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810861 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,873.15 | 09/01/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810885 |
| Principal investigator 1 | H. Lundbeck A S | $27.00 | 08/30/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059237823 |
| Recipient | PFIZER INC. | $40.50 | 08/30/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1045918939 |
| Recipient | PFIZER INC. | $500.00 | 08/30/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046309129 |
| Recipient | PFIZER INC. | $519.75 | 08/30/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046310347 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,860.10 | 08/23/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810983 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $40.50 | 08/23/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811033 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,906.15 | 08/18/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810947 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $202.50 | 08/18/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811009 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $81.00 | 08/18/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811021 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 08/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998396179 |
| Principal investigator 1 | ABBVIE INC. | $521.44 | 08/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998396193 |
| Principal investigator 1 | ABBVIE INC. | $630.00 | 08/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998396195 |
| Recipient | PFIZER INC. | $9,927.19 | 08/17/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046118545 |
| Recipient | PFIZER INC. | $14,868.00 | 08/17/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046161317 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 08/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811429 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 08/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811899 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 08/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811911 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 08/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811923 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 08/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811937 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 08/17/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811949 |
| Principal investigator 1 | ABBVIE INC. | $10,220.37 | 08/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998394993 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,095.45 | 08/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810787 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,295.55 | 08/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810923 |
| Principal investigator 1 | ABBVIE INC. | $1,514.16 | 08/09/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 998394333 |
| Principal investigator 1 | H. Lundbeck A S | $3,037.50 | 08/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) | No dispute reported | 06/30/2026 | 1059237321 |
| Principal investigator 1 | H. Lundbeck A S | $6,500.00 | 08/03/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A 1-YEAR TRIAL TO INFORM ABOUT LONG-TERM EXPOSURE TO EPTINEZUMAB IN PARTICIPANTS WITH CHRONIC CLUSTER HEADACHE (CCH) (CHRONICLE) | No dispute reported | 06/30/2026 | 1059237293 |
| Recipient | PFIZER INC. | $8,194.70 | 08/03/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046310361 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,487.70 | 08/01/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810825 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,392.45 | 08/01/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810875 |
| Principal investigator 1 | H. Lundbeck A S | $1,618.52 | 07/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059237139 |
| Principal investigator 1 | H. Lundbeck A S | $33.75 | 07/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059237145 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 07/27/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045897983 |
| Principal investigator 1 | PFIZER INC. | $952.90 | 07/27/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045948059 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 07/27/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045986172 |
| Principal investigator 1 | PFIZER INC. | $40.50 | 07/27/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046165693 |
| Principal investigator 1 | PFIZER INC. | $1,969.65 | 07/27/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046301809 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,487.70 | 07/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810801 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $545.40 | 07/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810811 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,919.70 | 07/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810849 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,808.80 | 07/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810997 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 07/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811419 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 07/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811837 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 07/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811851 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 07/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811863 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 07/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811875 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 07/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811887 |
| Principal investigator 1 | H. Lundbeck A S | $1,000.00 | 07/21/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | EPTINEZUMAB IN PARTICIPANTS WITH EPISODIC CLUSTER HEADACHE (ALLEVIATE) | No dispute reported | 06/30/2026 | 1059236985 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,418.45 | 07/18/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810959 |
| Principal investigator 1 | ABBVIE INC. | $202.50 | 07/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998391045 |
| Principal investigator 1 | PFIZER INC. | $1,310.72 | 07/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045922703 |
| Principal investigator 1 | PFIZER INC. | $2,160.00 | 07/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046035395 |
| Principal investigator 1 | PFIZER INC. | $11,325.05 | 07/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046067895 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,616.65 | 07/11/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810935 |
| Principal investigator 1 | ABBVIE INC. | $8,561.25 | 07/06/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998389391 |
| Principal investigator 1 | PFIZER INC. | $1,296.00 | 07/06/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1045999781 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 07/06/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046067775 |
| Principal investigator 1 | PFIZER INC. | $32,249.72 | 07/06/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046191075 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,679.60 | 07/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810837 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,231.90 | 07/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810899 |
| Principal investigator 1 | ABBVIE INC. | $4,376.99 | 07/03/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 998389209 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,398.15 | 06/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810753 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $40.50 | 06/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810765 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 06/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811407 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 06/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811803 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 06/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811815 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 06/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811826 |
| Principal investigator 1 | ABBVIE INC. | $405.00 | 06/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998387953 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 06/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045946737 |
| Principal investigator 1 | PFIZER INC. | $8,178.55 | 06/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046035415 |
| Principal investigator 1 | PFIZER INC. | $243.00 | 06/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046091547 |
| Principal investigator 1 | PFIZER INC. | $958.03 | 06/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046165109 |
| Principal investigator 1 | ABBVIE INC. | $700.00 | 06/21/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998387773 |
| Principal investigator 1 | H. Lundbeck A S | $27.00 | 06/21/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059236239 |
| Principal investigator 1 | H. Lundbeck A S | $3,628.19 | 06/21/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059236245 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,679.60 | 06/20/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810739 |
| Principal investigator 1 | PFIZER INC. | $2,186.03 | 06/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045889831 |
| Principal investigator 1 | PFIZER INC. | $4,320.00 | 06/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046257975 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,264.90 | 06/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810369 |
| Principal investigator 1 | PFIZER INC. | $4,082.85 | 06/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046214305 |
| Principal investigator 1 | PFIZER INC. | $243.00 | 06/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046258849 |
| Principal investigator 1 | PFIZER INC. | $13,787.55 | 06/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046260387 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,095.45 | 06/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810157 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $743.00 | 06/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810169 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $87.76 | 06/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810243 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,205.00 | 06/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810257 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,648.95 | 06/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810333 |
| Principal investigator 1 | ABBVIE INC. | $4,418.63 | 06/07/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998385591 |
| Principal investigator 1 | H. Lundbeck A S | $27.00 | 06/07/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059236049 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,807.35 | 05/30/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810133 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,840.15 | 05/30/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810423 |
| Recipient | PFIZER INC. | $18,568.02 | 05/25/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046076553 |
| Recipient | PFIZER INC. | $9,943.65 | 05/25/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046092371 |
| Recipient | PFIZER INC. | $40.50 | 05/25/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046185903 |
| Recipient | PFIZER INC. | $2,600.00 | 05/25/2023 | Covered Recipient Physician | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046204681 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811393 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811789 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $705.85 | 05/24/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810395 |
| Recipient | PFIZER INC. | $3,156.23 | 05/18/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045978727 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,681.95 | 05/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810379 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811381 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811693 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811705 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811719 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811731 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811743 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811755 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811767 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 05/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811779 |
| Principal investigator 1 | H. Lundbeck A S | $750.00 | 05/11/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059235763 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,711.90 | 05/09/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810181 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,455.40 | 05/09/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810345 |
| Principal investigator 1 | ABBVIE INC. | $7,971.38 | 05/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998380771 |
| Recipient | PFIZER INC. | $7,632.00 | 05/04/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1045936747 |
| Recipient | PFIZER INC. | $500.00 | 05/04/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1045988185 |
| Recipient | PFIZER INC. | $337.50 | 05/04/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046131131 |
| Recipient | PFIZER INC. | $371.25 | 05/04/2023 | Covered Recipient Physician | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046337105 |
| Principal investigator 1 | H. Lundbeck A S | $40.50 | 05/03/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059235531 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $121.50 | 05/03/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810221 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,840.15 | 05/03/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810321 |
| Principal investigator 1 | ABBVIE INC. | $183.57 | 04/27/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998379873 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,272.60 | 04/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810408 |
| Principal investigator 1 | ABBVIE INC. | $1,350.00 | 04/20/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | No dispute reported | 06/30/2026 | 998379031 |
| Principal investigator 1 | ABBVIE INC. | $700.00 | 04/20/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998379217 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,487.70 | 04/18/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810119 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 04/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811371 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 04/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811599 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 04/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811611 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 04/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811623 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 04/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811635 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 04/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811647 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 04/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811659 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 04/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811671 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 04/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811683 |
| Recipient | PFIZER INC. | $3,194.71 | 04/13/2023 | Covered Recipient Physician | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1045898447 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,487.70 | 04/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810193 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,621.65 | 04/13/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810357 |
| Principal investigator 1 | H. Lundbeck A S | $40.50 | 04/07/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059235029 |
| Principal investigator 1 | H. Lundbeck A S | $750.00 | 04/07/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) | No dispute reported | 06/30/2026 | 1059235035 |
| Principal investigator 1 | H. Lundbeck A S | $27.00 | 04/07/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059235041 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $200.00 | 04/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810093 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $440.40 | 04/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810105 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $140.40 | 04/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810145 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $345.20 | 04/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810207 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $40.50 | 04/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810233 |
| Principal investigator 1 | ABBVIE INC. | $3,875.25 | 03/30/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998376013 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $10,293.34 | 03/29/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046046253 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,679.60 | 03/29/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809811 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,205.30 | 03/29/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810069 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,391.50 | 03/21/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809859 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $705.85 | 03/21/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810009 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,456.80 | 03/21/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810021 |
| Principal investigator 1 | H. Lundbeck A S | $5,331.35 | 03/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059234461 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,461.80 | 03/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809971 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 03/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811356 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 03/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811575 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 03/14/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811589 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $600.75 | 03/09/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046111173 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $5,037.85 | 03/09/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046318253 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,711.90 | 03/08/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809761 |
| Principal investigator 1 | ABBVIE INC. | $4,077.75 | 03/02/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998372193 |
| Principal investigator 1 | H. Lundbeck A S | $54.00 | 03/01/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059234221 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,711.90 | 02/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809801 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $40.50 | 02/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809825 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,161.25 | 02/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810055 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $40.50 | 02/28/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810648 |
| Principal investigator 1 | Amgen Inc. | $500.00 | 02/24/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Medication Overuse Headache Study (MOH)_ | No dispute reported | 06/30/2026 | 1029651113 |
| Principal investigator 1 | Amgen Inc. | $500.00 | 02/24/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Phase P3 Pediatric Study (EM) | No dispute reported | 06/30/2026 | 1029657995 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $40.50 | 02/23/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1045963055 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $750.00 | 02/23/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046035381 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,095.45 | 02/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809789 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,295.05 | 02/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809871 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,295.55 | 02/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810033 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 02/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811341 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 02/22/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811561 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,196.57 | 02/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1045976643 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $4,434.88 | 02/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046184291 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $14,257.54 | 02/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046330367 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $8,820.00 | 02/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809835 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,744.90 | 02/16/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809983 |
| Principal investigator 1 | Amgen Inc. | $6,644.40 | 02/15/2023 | Non-covered Recipient Entity MICHIGAN HEAD PAIN & NEUROLOGICAL I | Erenumab (EMBRACE) | No dispute reported | 06/30/2026 | 1029650677 |
| Principal investigator 1 | Amgen Inc. | $16,611.00 | 02/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Ph3 Pediatric CM Study | No dispute reported | 06/30/2026 | 1029656377 |
| Principal investigator 1 | Amgen Inc. | $13,288.80 | 02/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Phase P3 Pediatric Study (EM) | No dispute reported | 06/30/2026 | 1029658001 |
| Principal investigator 1 | H. Lundbeck A S | $1,186.31 | 02/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059233771 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 02/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811331 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 02/15/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811549 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 02/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811317 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 02/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811501 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 02/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811513 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 02/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811527 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 02/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811539 |
| Principal investigator 1 | ABBVIE INC. | $9,918.75 | 02/09/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998369877 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,250.00 | 02/09/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046318165 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $6,268.10 | 02/09/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046332905 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,873.15 | 02/09/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809941 |
| Principal investigator 1 | ABBVIE INC. | $1,564.32 | 02/02/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998368629 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,487.70 | 02/02/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809749 |
| Principal investigator 1 | H. Lundbeck A S | $3,878.28 | 01/27/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059233475 |
| Principal investigator 1 | H. Lundbeck A S | $1,581.32 | 01/27/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) | No dispute reported | 06/30/2026 | 1059233479 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $10,397.75 | 01/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 4 OPENLABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF DAILY DOSING OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046011377 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $16,227.45 | 01/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046141869 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $803.25 | 01/26/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1046203497 |
| Principal investigator 1 | H. Lundbeck A S | $750.00 | 01/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059233355 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,621.65 | 01/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810045 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $40.50 | 01/25/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035810081 |
| Principal investigator 1 | Amgen Inc. | $6,320.00 | 01/24/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Ph3 Pediatric CM Study | No dispute reported | 06/30/2026 | 1029656371 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,167.30 | 01/20/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809847 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,424.15 | 01/20/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809995 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 01/19/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811305 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 01/19/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811441 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 01/19/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811453 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 01/19/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811465 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 01/19/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811477 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $698.25 | 01/19/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035811489 |
| Principal investigator 1 | H. Lundbeck A S | $54.00 | 01/18/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059233153 |
| Principal investigator 1 | Eli Lilly and Company | $399.59 | 01/13/2023 | Non-covered Recipient Entity MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE | A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 1038118011 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 01/12/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998366181 |
| Principal investigator 1 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $1,250.00 | 01/12/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE PC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1046014485 |
| Principal investigator 1 | H. Lundbeck A S | $27.00 | 01/11/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) WITH CHRONIC MIGRAINE (PROSPECT-2) | No dispute reported | 06/30/2026 | 1059233113 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,679.60 | 01/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809775 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,847.85 | 01/10/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809957 |
| Principal investigator 1 | Eli Lilly and Company | $92,866.00 | 01/06/2023 | Non-covered Recipient Entity MICHIGAN HEAD PAIN AND NEUROLOGICAL INSTITUTE | A PHASE 4 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | No dispute reported | 06/30/2026 | 1038111877 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $340.40 | 01/06/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809883 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,840.15 | 01/06/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE & NEUROLOGICAL INSTITURE | A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1035809931 |
| Principal investigator 1 | H. Lundbeck A S | $3,892.39 | 01/04/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL INSTITUTE | A STUDY WITH EPTINEZUMAB IN CHILDREN AND ADOLESCENTS (6 TO 17 YEARS) WITH CHRONIC OR EPISODIC MIGRAINE (REJOIN) | No dispute reported | 06/30/2026 | 1059232853 |
| Principal investigator 1 | ABBVIE INC. | $4,894.50 | 01/03/2023 | Non-covered Recipient Entity MICHIGAN HEADACHE AND NEUROLOGICAL | Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine | No dispute reported | 06/30/2026 | 998363579 |